Vimarsana
Biggest News Aggregation in the World

Page 14 - Evercore Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Evercore Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Evercore Inc Today - Breaking & Trending Today

Activist Investing Today: Evercore's Gloria Lin - Vimarsana News

Activist Investing Today: Evercore's Gloria Lin

Managing director Gloria Lin, who focuses on strategic defense + shareholder advisory, discusses the pros + cons of defense PIPE infusions and more.

Evercore Increases Magna International (NYSE:MGA) Price Target to $75.00 - Vimarsana News

Evercore Increases Magna International (NYSE:MGA) Price Target to $75.00

Magna International (NYSE:MGA – Get Free Report) (TSE:MG) had its price objective raised by Evercore from $70.00 to $75.00 in a note issued to investors on Tuesday, BayStreet.CA reports. The firm presently has an “outperform” rating on the stock. Evercore’s target price points to a potential upside of 45.97% from the company’s previous close. Other […]

There's a good reason why Wall Street is overpaying bankers - Vimarsana News

There's a good reason why Wall Street is overpaying bankers

Morgan Stanley CEO James Gorman predicts a rebound in deals once the Federal Reserve signals it’s done raising interest rates, so better to lock in the talent now

Nature's Touch Frozen Foods, LLC acquired Certain frozen fruit assets from SunOpta Inc. for transaction valued at approximately $140 million. - Vimarsana News

Nature's Touch Frozen Foods, LLC acquired Certain frozen fruit assets from SunOpta Inc. for transaction valued at approximately $140 million.

Nature's Touch Frozen Foods, LLC acquired Certain frozen fruit assets from SunOpta Inc. for transaction valued at approximately $140 million on October 12, 2023. The transaction is valued at $141...

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Thera - Vimarsana News

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Thera

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Ce...